SetPoint Medical’s Funding Signals Investor Faith in Neuromodulation for Autoimmune Diseases

SetPoint Medical recently secured $140 million in private financing to advance the commercial rollout of its SetPoint System. The funding not only marks a significant milestone in neuroimmune therapy for rheumatoid arthritis (RA), it also underscores strong investor confidence in pioneering neuromodulation approaches to treating chronic autoimmune conditions, according to GlobalData.

The SetPoint System targets the body’s neural pathways to modulate the immune response, offering a non-pharmacological therapy that could significantly reduce reliance on traditional drugs such as biologics and immunosuppressants. By directly engaging the neuroimmune axis, SetPoint aims to deliver precision therapy that can adapt dynamically to an individual’s disease activity.

“The funding raised by SetPoint Medical reflects growing enthusiasm for neuromodulation-based therapies in autoimmune disease management,” GlobalData Medical Analyst Graysen Vigneux said. “As treatment paradigms shift toward precision and personalization, neuromodulation presents a compelling complement, or alternative, to conventional pharmacotherapy.”

Neuroimmune modulation represents a fast-emerging frontier in treating inflammatory diseases by manipulating neural circuits to control immune system behavior. SetPoint’s technology leverages insights into vagus nerve stimulation to attenuate pro-inflammatory signaling, a strategy that aligns with the increasing interest in bioelectronic medicine.

The funding secured by SetPoint is earmarked to support regulatory and clinical development, scale up manufacturing capabilities, expand commercial infrastructure, including reimbursement strategies and provider education, and fuel strategic partnerships with biopharma and healthcare institutions.

“With the funding, SetPoint is well-positioned not only to bring its neuroimmune platform to market but also to catalyze broader acceptance of bioelectronic medicine in autoimmune care,” Vigneux stated. “By accelerating both regulatory and go-to-market efforts, the funding propels SetPoint toward making its neuroimmune therapy accessible to patients, potentially transforming the RA treatment landscape by offering a durable, device-based solution.”